| pubmed-article:18374569 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18374569 | lifeskim:mentions | umls-concept:C0206529 | lld:lifeskim |
| pubmed-article:18374569 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:18374569 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:18374569 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:18374569 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:18374569 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:18374569 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:18374569 | pubmed:dateCreated | 2008-4-15 | lld:pubmed |
| pubmed-article:18374569 | pubmed:abstractText | A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Replacement of the (2-aryl)-ethynyl-moiety in 8-position with smaller less lipophilic substituents produced compounds inhibiting the binding of [3H]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both mGluR2 and mGluR3. These compounds were able to reverse LY354740-mediated inhibition of field excitatory postsynaptic potentials in the rat dentate gyrus and in vivo activity could be demonstrated by reversal of the LY354740-induced hypoactivity in mice after oral administration. | lld:pubmed |
| pubmed-article:18374569 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18374569 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18374569 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18374569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18374569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18374569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18374569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18374569 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18374569 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:18374569 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:GattiSilviaS | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:BallardTheres... | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:AdamGeoG | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:HuwylerJörgJ | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:MutelVincentV | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:KewJames N... | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:GoetschiErwin... | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:KnoflachFrédé... | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:WichmannJürge... | lld:pubmed |
| pubmed-article:18374569 | pubmed:author | pubmed-author:WolteringThom... | lld:pubmed |
| pubmed-article:18374569 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18374569 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18374569 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:18374569 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18374569 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18374569 | pubmed:pagination | 2725-9 | lld:pubmed |
| pubmed-article:18374569 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:meshHeading | pubmed-meshheading:18374569... | lld:pubmed |
| pubmed-article:18374569 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18374569 | pubmed:articleTitle | Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists. | lld:pubmed |
| pubmed-article:18374569 | pubmed:affiliation | F. Hoffmann-La Roche Ltd., Pharma Discovery Chemistry CNS, CH-4070 Basel, Switzerland. thomas.woltering@roche.com | lld:pubmed |
| pubmed-article:18374569 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:18374569 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18374569 | lld:pubmed |
